News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|March 25, 2025

Sexual Problems and Neurogenic Bladder

Author(s)Tamara Kaplan, MD

Panelist discusses how managing bladder and sexual dysfunction in neurological care requires addressing access barriers, fostering open communication, recognizing symptom overlap, understanding medication adverse effects, and providing gender-specific care.

Episodes in this series

EP. 1 Addressing Neurogenic Bladder: Understanding Prevalence, Unmet Needs, and Effective Management

EP. 1 Addressing Neurogenic Bladder: Understanding Prevalence, Unmet Needs, and Effective Management

EP. 2 Lower Urinary Tract Overview

EP. 2 Lower Urinary Tract Overview

EP. 3 Neurogenic Bladder: Challenges in Diagnosis

EP. 3 Neurogenic Bladder: Challenges in Diagnosis

EP. 4 Role of Patient History in Neurogenic Bladder Diagnosis

EP. 4 Role of Patient History in Neurogenic Bladder Diagnosis

EP. 5 Neurological Conditions and Bladder Dysfunction

EP. 5 Neurological Conditions and Bladder Dysfunction

EP. 6 Treatments for Neurogenic Bladder

EP. 6 Treatments for Neurogenic Bladder

EP. 7 Neurogenic Bladder and Multidisciplinary Care

EP. 7 Neurogenic Bladder and Multidisciplinary Care

EP. 8 Sexual Problems and Neurogenic Bladder

EP. 8 Sexual Problems and Neurogenic Bladder

EP. 9 Management of Neurogenic Bladder

EP. 9 Management of Neurogenic Bladder

Video content above is prompted by the following:

What are the common barriers patients face in seeking treatment for bladder issues?
How can neurologists ensure their patients feel heard and understood when discussing bladder symptoms?
How do bladder dysfunction and sexual problems overlap in patients with neurologic conditions?
What should neurologists be aware of regarding iatrogenic sexual problems caused by neurological medications?
How can neurologists address female sexual dysfunction in their patients?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

NeurologyLive® Brain Games: November 16, 2025

ByMarco Meglio,Louie Pasculli

November 16th 2025

Carla Tortorella, MD, PhD

Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows

ByLouie Pasculli

November 15th 2025

Elena Grebenciucova, MD, on Evolving Standards in NMOSD Diagnosis and Management

ByElena Grebenciucova, MD,Marco Meglio

November 15th 2025

BBP-418 Success in LGMD, Alixorexton Improves Narcolepsy Symptoms, Fenebrutinib Meets Phase 3 End Points

ByNeurologyLive® Staff

November 15th 2025

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy

ByIsabella Ciccone, MPH

November 14th 2025

Latest CME

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy

Using Machine Learning for Risk Prediction in Multiple Sclerosis Following DMT Discontinuation: Marisa McGinley, DO

NeurologyLive® Brain Games: November 16, 2025

BBP-418 Success in LGMD, Alixorexton Improves Narcolepsy Symptoms, Fenebrutinib Meets Phase 3 End Points

© 2025 MJH Life Sciences^®

All rights reserved.